BlossomHill Therapeutics Closes $100 Million Series B Financing
Summary
SAN DIEGO, Calif., February 29, 2024-- BlossomHill Therapeutics, Inc., a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the closing of a $100 million Series B financing round. In conjunction with the financing round, Sundeep Agrawal, M.D., General Partner at Colt Ventures, and Timothy Stubbs, M.D., Principal at Vivo Capital, will join the BlossomHill Board of Directors. Combining human intelligence, creative thinking, and proven drug design expertise, the company is developing small molecules with the potential to redefine the gold standard for cancer and autoimmune disease treatment. Since its founding, the company has made rapid progress on its drug discovery programs, and we look forward to the generation of clinical data as BlossomHill enters its next phase, added Carl Gordon, Ph.D., Managing Partner, OrbiMed Advisors. Headquartered in San Diego, California, BlossomHill Therapeutics is supported by a strong syndicate of leading investors, including Cormorant Asset Management, OrbiMed, Vivo Capital and Colt Ventures.